Author: Willem van Lawick

Amsterdam, The Netherlands, August 1, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing a T-cell immunotherapy product candidate designed to reduce Graft versus Host Disease (GVHD) and relapse after hematopoietic stem cell transplantations (HSCT), today announces that it has received a new… Continue reading Kiadis Pharma secures €20 million debt financing facility from Kreos Capital

Significantly strengthened cash position; raised over EUR 60 million in equity and debt (gross, including raise in March 2018) Filed Marketing Authorization Application with the European Medicines Agency for ATIR101 in blood cancers Received Regenerative Medicine Advanced Therapy designation from the US FDA First patient enrolled in Phase 3 trial for ATIR101 in adult patients… Continue reading Annual Results for the year ended December 31, 2017

Responses submitted to EMA Day 120 list of questions Amsterdam, The Netherlands, March 28, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing a T-cell immunotherapy product candidate designed to reduce Graft versus Host Disease (GVHD) in hematopoietic stem cell transplantations (HSCT), today… Continue reading Kiadis Pharma on track with European regulatory review for ATIR101

Amsterdam, The Netherlands, March 13, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing a T-cell immunotherapy product designed to reduce Graft versus Host Disease (GVHD) in hematopoietic stem cell transplantations (HSCT), today announces that it has raised gross proceeds of €23.4 million… Continue reading Kiadis Pharma raises €23.4 million in a private placement of 2.6 million new shares

Amsterdam, The Netherlands, March 12, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing a T-cell immunotherapy product designed to reduce Graft versus Host Disease (GVHD) in hematopoietic stem cell transplantations (HSCT) today announces the launch of a private placement of approximately 2.6… Continue reading Kiadis Pharma launches a private placement of approximately 2.6 million new shares